Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of Parkinson’s disease

BMC Neuroscience

Myung Koo Lee¹  Chong Kil Lee¹  Bang Yeon Hwang¹  Hyun Jin Park¹  Keun Hong Park¹  Ting Ting Zhao¹  Keon Sung Shin¹ 

[1] College of Pharmacy and Research Center for Bioresource and Health, Chungbuk National University, 1, Chungdae-ro, Cheongju 362-763, Seowon-gu, Republic of Korea

关键词: Adjuvant therapeutics;    ERK1/2;    ∆FosB;    Body and locomotive AIMs scores;    Dyskinesia;    6-Hydroxydopamine-lesioned rats;    Gynostemma pentaphyllum;   

Others  :  1211793
DOI  :  10.1186/s12868-015-0163-5

 received in 2015-01-14, accepted in 2015-04-10,  发布年份 2015

【 摘 要 】

Background

Gypenosides (GPS) and ethanol extract of Gynostemma pentaphyllum (GP-EX) show anxiolytic effects on affective disorders in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of Parkinson’s disease (PD). Long-term administration of L-3,4-dihydroxyphenylalanine (L-DOPA) leads to the development of severe motor side effects such as L-DOPA-induced-dyskinesia (LID) in PD. The present study investigated the effects of GPS and GP-EX on LID in a 6-hydroxydopamine (6-OHDA)-lesioned rat model of PD.

Results

Daily administration of L-DOPA (25 mg/kg) in the 6-OHDA-lesioned rat model of PD for 22 days induced expression of LID, which was determined by the body and locomotive AIMs scores and contralateral rotational behaviors. However, co-treatments of GPS (25 and 50 mg/kg) or GP-EX (50 mg/kg) with L-DOPA significantly attenuated the development of LID without compromising the anti-parkinsonian effects of L-DOPA. In addition, the increases in ∆FosB expression and ERK1/2 phosphorylation in 6-OHDA-lesioned rats induced by L-DOPA administration were significantly reduced by co-treatment with GPS (25 and 50 mg/kg) or GP-EX (50 mg/kg).

Conclusion

These results suggest that GPS (25 and 50 mg/kg) and GP-EX (50 mg/kg) effectively attenuate the development of LID by modulating the biomarker activities of ∆FosB expression and ERK1/2 phosphorylation in the 6-OHDA-lesioned rat model of PD. GPS and GP-EX will be useful adjuvant therapeutics for LID in PD.

【 授权许可】

   
2015 Shin et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Fearnley JM, Lees AJ: Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 1991, 114:2283-301.
• [2]Marsden CD: Parkinson’s disease. J Neurol Neurosurg Psychiatry 1994, 57:672-81.
• [3]Fahn S: Description of Parkinson’s disease as a clinical syndrome. Ann NY Acad Sci 2003, 991:1-14.
• [4]Jankovic J: Motor fluctuations and dyskinesias in Parkinson’s disease: clinical manifestations. Mov Disord 2005, 20:S11-6.
• [5]Olanow CW, Damier P, Goetz CG, Mueller T, Nutt J, Rascol O, et al.: Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the Splendid Study). Clin Neuropharmacol 2004, 27:58-62.
• [6]Encarnacion EV, Hauser RA: Levodopa-induced dyskinesias in Parkinson’s disease: etiology, impact on quality of life, and treatments. Eur Neurol 2008, 60:57-66.
• [7]Andersson M, Konradi C, Cenci MA: cAMP response element-binding protein is required for dopamine-dependent gene expression in the intact but not the dopamine-denervated striatum. J Neurosci 2001, 21:9930-43.
• [8]Pavón N, Martín AB, Mendialdua A, Moratalla R: ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol Psychiatry 2006, 59:64-74.
• [9]Andersson M, Hilbertson A, Cenci MA: Striatal fosB expression is causally linked with L-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson’s disease. Neurobiol Dis 1999, 6:461-74.
• [10]Gerfen CR, Miyachi S, Paletzki R, Brown P: D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J Neurosci 2002, 22:5042-54.
• [11]Zhen X, Torres C, Cai G, Friedman E: Inhibition of protein tyrosine/mitogen-activated protein kinase phosphatase activity is associated with D2 dopamine receptor supersensitivity in a rat model of Parkinson’s disease. Mol Pharmacol 2002, 62:1356-63.
• [12]Razmovski-Naumovski V, Huang TH-W, Tran VH, Li GQ, Duke CC, Roufogalis BD: Chemistry and pharmacology of Gynostemma pentaphyllum. Phytochemistry 2005, 14:197-219.
• [13]Shin KS, Zhao TT, Choi HS, Hwang BY, Lee CK, Lee MK: Effects of gypenosides on anxiety disorders in MPTP-lesioned mouse model of Parkinson’s disease. Brain Res 2014, 1567:57-65.
• [14]Wang P, Niu L, Gao L, Li WX, Jia D, Wang XL, et al.: Neuroprotective effect of gypenosides against oxidative injury in the substantia nigra of a mouse model of Parkinson’s disease. J Int Med Res 2010, 38:1084-92.
• [15]Choi HS, Park MS, Kim SH, Hwang BY, Lee CK, Lee MK. Neuroprotective effects of herbal ethanol extractsf rom Gynostemma pentaphyllum in the 6-hydroxydopamine-lesioned rat model of Parkinson’s disease. Molecules. 2010;15:2814–24.
• [16]Choi HS, Zhao TT, Shin KS, Kim SH, Hwang BY, Lee CK, et al.: Anxiolytic effects of herbal ethanol extract from Gynostemma pentaphyllum after exposure to chronic stress in mice. Molecules 2013, 18:4342-56.
• [17]Zhang H, Ma L, Wang F, Chen J, Zhen X: Chronic SKF83959 induced less severe dyskinesia and attenuated L-dopa-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson’s disease. Neuropharmacology 2007, 53:125-33.
• [18]Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA: Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson’s disease. Eur J Neurosci 2002, 15:120-32.
• [19]Cenci MA, Tranberg A, Andersson M, Hilbertson A: Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment. Neuroscience 1999, 9:4515-27.
• [20]Ulusoy A, Sahin G, Kirik D: Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA-induced dyskinesia in rats. Proc Natl Acad Sci U S A 2010, 107:13159-64.
• [21]Westin JE, Vercammen L, Strome EM, Konradi C, Cenci MA: Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol Psychiatry 2007, 62:800-10.
• [22]Quinn N: Drug treatment of Parkinson’s disease. Br Med J 1995, 310:575-9.
• [23]Rascol O, Fabre N: Dyskinesia: L-dopa-induced and tardive dyskinesia. Clin Neuropharmacol 2001, 24:313-23.
• [24]Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM: The pharmacology of L-DOPA-induced dyskinesia in Parkinson’s disease. Pharmacol Rev 2013, 65:171-222.
• [25]Park KH, Park HJ, Shin KS, Lee MK: Multiple treatments with L-3,4-dihydroxyphenylalanine modulate dopamine biosynthesis and neurotoxicity through the protein kinase A-transient extracellular signal-regulated kinase and exchange protein activation by cyclic AMP-sustained extracellular signal-regulated kinase signaling pathways. J Neurosci Res 2014, 92:1746-56.
• [26]Wang P, Niu L, Guo XD, Gao L, Li WX, Jia D: Gypenosides protects dopaminergic neurons in primary culture against MPP+-induced oxidative injury. Brain Res Bull 2010, 83:266-71.
• [27]Liu XR, Wang YX, Wang SL: Research on antioxidant effects of gypenosides. Chin Herb Res 1998, 4:22-3.
• [28]Tanner MA, Bu X, Steimle JA, Myers PR: The direct release of nitric oxide by gypenosides derived from the herb Gynostemma pentaphyllum. Nitric Oxide 1999, 3:359-65.
• [29]Shang LS, Liu JC, Zhu QJ, Zhao L, Feng YX, Wang XP, et al.: Gypenosides protect primary cultures of rat cortical cells against oxidative neurotoxicity. Brain Res 2006, 1120:163-74.
• [30]Im SA, Choi HS, Hwang BY, Lee MK, Lee CK: Augmentation of immune responses by oral administration of Gynostemma pentaphyllum ethanol extract. Kor J Pharmacog 2009, 40:35-40.
• [31]Zhang L, Dawson VL, Dawson TM: Role of nitric oxide in Parkinson’s disease. Pharmacol Ther 2006, 109:33-41.
• [32]Padovan-Neto FE, Echeverry MB, Tumas V, Del-Bel EA: Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson’s disease. Neuroscience 2009, 159:927-35.
• [33]Takuma K, Tanaka T, Takahashi T, Hiramatsu N, Ota Y, Ago Y, et al.: Neuronal nitric oxide synthase inhibition attenuates the development of L-DOPA-induced dyskinesia in hemi-Parkinsonian rats. Eur J Pharmacol 2012, 683:166-73.
• [34]Carta M, Bezard E: Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia. Neuroscience 2011, 198:245-51.
• [35]Guo WY, Wang WX: In: cultivation and utilization of Gynostemma pentaphyllum. Publishing House of Electronics, Science and Technology University, Beijing; 1993.
• [36]Mo J, Zhang H, Yu LP, Sun PH, Jin GZ, Zhen X: L-Stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson’s disease. Neurobiol Aging 2010, 31:926-36.
• [37]Cenci MA, Lee CS, Björklund A: L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 1998, 10:2694-706.
• [38]Grande C, Zhu H, Martín AB, Lee M, Ortiz O, Hiroi N, et al.: Chronic treatment with atypical neuroleptics induces striosomal FosB/DeltaFosB expression in rats. Biol Psychiatry 2004, 55:457-63.